10x Genomics, Inc.
General ticker "TXG" information:
- Sector: Health Care
- Industry: Medical - Healthcare Information Services
- Capitalization: $1.5B (TTM average)
10x Genomics, Inc. follows the US Stock Market performance with the rate: 60.8%.
Estimated limits based on current volatility of 2.7%: low 20.21$, high 21.32$
Factors to consider:
- Earnings expected soon, date: 2026-02-11 bmo
- Total employees count: 1306 as of 2024
- US accounted for 54.7% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Fluctuating operating results, Government funding dependency, Geopolitical risks, Ability to compete, Product transition management
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [9.83$, 23.68$]
- 2025-12-31 to 2026-12-31 estimated range: [9.42$, 22.48$]
Financial Metrics affecting the TXG estimates:
- Negative: with PPE of -9.4 at the end of fiscal year the price was high
- Negative: negative Operating income
- Positive: Inventory ratio change, % of 0.36 <= 0.79
- Positive: Shareholder equity ratio, % of 77.30 > 64.37
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: 0 < Operating cash flow per share per price, % of 0.39
- Negative: negative Net income
Short-term TXG quotes
Long-term TXG plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $516.41MM | $618.73MM | $610.78MM |
| Operating Expenses | $684.35MM | $884.06MM | $805.34MM |
| Operating Income | $-167.94MM | $-265.33MM | $-194.56MM |
| Non-Operating Income | $5.97MM | $16.57MM | $16.86MM |
| Interest Expense | $0.48MM | $0.03MM | $0.00MM |
| R&D Expense | $265.67MM | $331.31MM | $264.70MM |
| Income(Loss) | $-161.97MM | $-248.76MM | $-177.70MM |
| Taxes | $4.03MM | $6.34MM | $4.93MM |
| Profit(Loss)* | $-166.00MM | $-255.10MM | $-182.63MM |
| Stockholders Equity | $805.74MM | $741.04MM | $710.13MM |
| Inventory | $81.63MM | $73.71MM | $83.11MM |
| Assets | $1,028.98MM | $965.14MM | $918.64MM |
| Operating Cash Flow | $-33.61MM | $-15.20MM | $6.66MM |
| Capital expenditure | $131.66MM | $49.52MM | $12.39MM |
| Investing Cash Flow | $-350.89MM | $133.49MM | $-32.63MM |
| Financing Cash Flow | $15.82MM | $13.67MM | $10.91MM |
| Earnings Per Share** | $-1.46 | $-2.18 | $-1.52 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.